Experimental drug combination selectively destroys lymphoma cells
Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective new therapy for several forms of blood cancer, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).
Massey debunks common cancer myths for World Cancer Day
February 4, 2013 is World Cancer Day. This global initiative by the Union for International Cancer Control aims to unite the world together in the fight against cancer by educating and raising awareness. VCU Massey Cancer Center is taking part in this initiative by debunking the following common cancer myths:
Together with CHoR, Massey is first in Virginia to receive advanced certification for palliative care
Virginia Commonwealth University Massey Cancer Center and Children's Hospital of Richmond at VCU (CHoR) have jointly earned The Joint Commission's Gold Seal of Approval® for their palliative care programs, making them the first and only certified palliative care programs in Virginia. Palliative care provides specialized, multidisciplinary care for patients with serious illnesses, including but not limited to cancer, by addressing physical, emotional, social and spiritual needs.
Five tips for maintaining a healthy weight
According to the American Cancer Society (ACS), more than half of all cancer deaths could be prevented by making healthy choices like not smoking, maintaining a healthy weight, eating nutritiously and staying physically active. As January marks the start of new beginnings, here are five tips to help you keep your healthy weight resolutions this year.
Multiple sclerosis drug may one day treat colorectal cancer
After uncovering a mechanism that promotes chronic intestinal inflammation and the development of colorectal cancer, scientists from Virginia Commonwealth University Massey Cancer Center have found that fingolimod, a drug currently approved for the treatment of multiple sclerosis, could potentially eliminate or reduce the progression of colitis-associated cancer (CAC).